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Abstract
Background: Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal
development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood
biomarkers. A potential biomarker is neurofilament light (NF-L), due to its association with axonal damage in
neurodegenerative conditions.
Methods: We measured blood NF-L concentrations in 100 adults with DS using Simoa NF-light® assays, and we
examined relationships with age as well as cross-sectional and longitudinal dementia diagnosis.
Results: NF-L concentrations increased with age (Spearman’s rho = 0.789, p < 0.001), with a steep increase after
age 40, and they were predictive of dementia status (p = 0.022 adjusting for age, sex, and APOE4), but they showed
no relationship with long-standing epilepsy or premorbid ability. Baseline NF-L concentrations were associated with
longitudinal dementia status.
Conclusions: NF-L is a biomarker for neurodegeneration in DS with potential for use in future clinical trials to
prevent or delay dementia.
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Background
Down syndrome (DS), caused by the trisomy, transloca-
tion, or partial trisomy of chromosome 21, is the most
common genetic cause of intellectual disability (ID), with
an estimated population prevalence of 6 million world-
wide. Dementia is a common feature of the aging
process in DS that is due to the triplication of the amyl-
oid precursor protein on chromosome 21, leading to
brain pathology indicative of Alzheimer’s disease (AD)
[1], with a cumulative incidence for dementia in excess
of 90% by the age of 65 [2] and a mean age at dementia
diagnosis of 55 [3]. DS is therefore a genetic form of AD
alongside autosomal dominant causes of AD [4].
Neurofilament light (NF-L) is one of the scaffolding
cytoskeleton proteins of myelinated subcortical axons
[5] and can now be reliably measured in blood using
ultrasensitive single-molecule array (Simoa) technology.
Blood concentration of NF-L correlates well with corre-
sponding cerebrospinal fluid (CSF) measures [6] and
reflects axonal damage in neurological disorders, includ-
ing frontotemporal dementia [7], multiple sclerosis [8],
and familial and sporadic AD [9, 10]. NF-L correlates
with other measures of disease stage and severity [10],
but the utility of NF-L in populations with other genetic
forms of AD is yet to be fully explored.
Aging in DS is invariably associated with AD path-
ology, and this condition therefore presents an oppor-
tunity to confirm the relationship between NF-L and
progression of AD pathology. Furthermore, DS is a
critically important group for clinical trials of treatments
to prevent and delay AD pathology and dementia symp-
toms, and a reliable blood biomarker would help to
address disease burden in this vulnerable population by
enabling clinical trials of disease-modifying treatments.
In the present study, we aimed to explore the relation-
ship between plasma NF-L levels, age, and dementia
status in individuals with DS, as well as its independence
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from sex effects, premorbid intellectual ability levels,
and long-standing epilepsy.
Methods
Participants aged 16 years and older were recruited across
England via care homes, support groups, and local NHS
sites. Participants with an acute physical or mental health
condition were excluded until they had recovered; other
details of the cohort have been described previously [11].
DS status was confirmed using DNA from saliva or blood
and genotyped using OmniExpressExome arrays (Illumina,
San Diego, CA, USA); trisomy status was visually con-
firmed in GenomeStudio software (Illumina) (see Table 1).
Apolipoprotein E (APOE) status was determined using
TaqMan assays for rs7412 and rs429358 (Thermo Fisher
Scientific, Waltham, MA, USA).
Assessment included a detailed interview with carers
using the Cambridge Examination of Mental Disorders of
Older People with Down’s syndrome and others with in-
tellectual disabilities [12] to determine decline in several
domains, including memory. Premorbid ID level was
defined according to the International Classification of
Diseases, Tenth Revision, diagnostic system’s descriptions
of mild, moderate, and severe ID, based on carers’ reports
of the individuals’ best-ever level of functioning [13]. At
baseline, dementia was defined as a confirmed clinical
diagnosis. At follow-up, participants were classified ac-
cording to whether they had retained or been given a diag-
nosis of dementia or were being investigated for dementia.
Blood samples from 100 individuals were collected in
lithium heparin tubes (Fisher Scientific UK, Loughborough,
UK) and sent overnight for processing. Blood was layered
over a similar amount of Ficoll (GE Healthcare, Little
Chalfont, UK), then centrifuged in a swing-out rotor for 40
minutes at 400 × g without braking. Plasma samples were
stored at − 80 °C. Plasma NF-L concentration was mea-
sured by the same laboratory technician with reagents from
a single lot using the Simoa NF-light® assay (a digital sand-
wich immunoassay employing antibodies directed against
the rod domain of NF-L) on an HD-1 Simoa analyzer
according to the protocol issued by the manufacturer
(Quanterix, Lexington, MA, USA). Samples were run in
duplicate, and coefficients of variation (CVs) for dupli-
cates were set to be < 12%. All samples measured
within the range spanned by the limits of quantification
and interassay CV for the high- and low-concentration
quality controls were 6.6% and 8.1%, respectively.
All statistical tests were two-sided, and statistical sig-
nificance was set at p < 0.05. We tested associations
between plasma NF-L samples and demographic or clin-
ical factors using Mann-Whiney U, Kruskal-Wallis, and
Spearman’s rank correlation tests as appropriate. Associa-
tions between plasma NF-L and dementia diagnosis were
tested using logistic regression and log-transformed NF-L
values, with adjustment for age and sex; we also adjusted
for APOE4 status cross-sectionally.
Results
NF-L levels were obtained from 100 participants (age
range 17–73 years). Five results were excluded after
failing to meet CV thresholds, meaning 95 adults were
included in subsequent analyses. Of adults aged 36 and
older who are being targeted for longitudinal follow-up,
29 of 63 (46%) had completed a follow-up assessment at
the time of this report (mean number of months be-
tween assessments 23.4, SD 3.9). One individual had
Table 1 Demographics of all participants included in group and subgroup analyses
All participants Dementia (baseline) No dementia (baseline) Participants with follow-up data
Number of subjects 94 18 76 29
Age at baseline, years,
mean ± SD (range)
42.68 ± 14.87 (17–73) 55.17 ± 9.92 (40–69) 39.72 ± 14.34 (17–73) 52.63 ± 8.88 (40–72)
DS type 89 (94.7%) trisomy, 2 (2.1%)
translocation, 3 (3.2%)
unknown
18 (100.0%) trisomy 71 (93.4%) trisomy, 2
(2.6%) translocation, 3
(3.9%) unknown
28 (96.6%) trisomy, 1 (3.4%)
unknown
Sex 41 (43.6%) female, 53
(56.4%) male
6 (33.3%) female, 12 (66.7%)
male
35 (46.1%) female, 41
(55.9%) male
10 (34.5%) female, 19 (65.5%)
male
Ethnicity 85 (90.4%) white, 9 (9.6%)
other
17 (94.4.0%) white, 1 (5.6%)
other
68 (89.5%) white, 8 (10.5%)
other
27 (93.1%) white, 2 (6.8%)
other
Predementia ID level 37 (39.4%) mild, 47 (50%)
moderate, 9 (9.6%) severe,
1 (1.2%) unknown
6 (33.3%) mild, 9 (50.0%)
moderate, 3 (16.7%) severe
31 (40.8%) mild, 38 (50%)
moderate, 6 (7.9%) severe, 1
(1.3%) unknown
13 (44.8%) mild, 12 (41.4%)
moderate, 3 (10.3%) severe,
1 (3.4%) unknown
APOE status 68 (72.3%) non-APOE4 carrier,
23 (24.5%) APOE4 carrier, 3
(3.2%) unknown
12 (66.7%) non-APOE4 carrier,
5 (27.8%) APOE4 carrier, 1
(5.5%) unknown
56 (73.7%) non-APOE4 carrier,
18 (23.7%) APOE4 carrier, 2
(2.6%) unknown
22 (75.9%) non-APOE4
carriers, 6 (20.7%) APOE4
carrier, 1 (3.4%) unknown
NF-L level, ng/L,
median (range)
22.74 (6.11–136.91) 63.76 (15.21–136.91) 19.96 (6.11–116.84) 32.67 (12.23–481.97)
Abbreviations: DS Down syndrome, ID Intellectual disability, APOE Apolipoprotein E, APOE4, Apolipoprotein E E4 allele, NF-L Neurofilament light
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experienced an occlusive cerebrovascular event 4–6
months prior to donating the blood sample and con-
verted to dementia status at follow-up but was an outlier
with an NF-L level of 481.97 ng/L; thus, this individual
was excluded from cross-sectional analysis. Among the
remaining 94 individuals, NF-L concentration had a
median value of 22.74 ng/L (range 6.11–136.91 ng/L). At
baseline, 18 of 94 participants had a clinical diagnosis of
dementia (Table 1).
NF-L levels and relationship with dementia and other
clinical variables
NF-L levels did not differ by premorbid ID level (Kruskal-
Wallis test, p = 0.195), sex (Mann-Whitney U test, p = 0.
837) or long-standing epilepsy (Mann-Whitney U test, p =
0.858). NF-L level and age of participants were significantly
correlated (Spearman’s rho = 0.789, p < 0.001) (Fig. 1), such
that those aged 35 and older had significantly higher levels
of NF-L than younger individuals (median 11.52 ng/L vs.
32.42 ng/L, Mann-Whitney U test p < 0.001).
Those with dementia had significantly higher levels of
NF-L (median 63.76 ng/L vs. 19.96 ng/L; Mann-Whitney
U test p < 0.001), and a logistic regression model adjusting
for age, sex, and APOE4 status revealed that NF-L levels
remained predictive of dementia status (p = 0.022).
NF-L and predictive validity for dementia
Seven (24.1%) of 29 individuals with follow-up cognitive
data had a clinical diagnosis of dementia at baseline, all
with the dementia diagnosis retained at follow-up, with
a further 2 (6.9%) individuals converting to dementia
status by follow-up, whereas 3 (10.3%) participants were
under investigation for dementia at follow-up. Predictive
validity of NF-L levels at baseline was explored by com-
bining individuals with confirmed or suspected dementia
at follow-up (n = 12, median NF-L 77.38 ng/L) and com-
paring them with those who remained dementia-free
(median NF-L 19.94 ng/L). Higher levels of NF-L at
baseline predicted the likelihood of dementia at follow-
up, even when adjusted for age and sex (p = 0.036).
Discussion
We have demonstrated that NF-L measured in blood
using an ultrasensitive assay is strongly associated with
age and dementia status in individuals with DS, and
baseline levels were predictive of dementia diagnosis
over time. Furthermore, NF-L levels did not differ ac-
cording to severity of premorbid ID or by long-standing
epilepsy diagnosis (a common neurological comorbidity
in DS), suggesting that it is a stable and feasible bio-
marker that can be used in clinical populations.
Our results indicate that this marker could pinpoint the
onset of neurodegeneration in DS. NF-L showed an age
relationship in keeping with postmortem data and amyloid
positron emission tomography studies of AD pathology in
adults with DS [1, 14, 15]. In familial AD, serum NF-L
concentration is increased prior to symptom onset and
correlates with measures of disease stage and severity [10].
In sporadic AD, plasma NF-L concentration is increased
already in the mild cognitive impairment stage of the
Fig. 1 Neurofilament light (NF-L) concentration by age and dementia status of individuals with Down syndrome
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disease and correlates with cognitive hallmarks of the dis-
ease [9]. Our results show that NF-L has similar relation-
ships with clinical dementia diagnoses in DS. Substantial
neurodegeneration associated with the buildup of amyloid
likely occurs before a threshold for dementia diagnosis is
reached, and like the presence of amyloid plaques preced-
ing the clinical signs by several decades, NF-L levels may
be increased some time before onset of significant symp-
toms, in keeping with some degree of neurodegeneration
prior to clinical impact. Further longitudinal studies may
elucidate the relationship between NF-L levels and devel-
opment of symptoms in genetically predisposed popula-
tions such as DS.
Although NF-L is a marker of axonal damage, and
thus not specific to AD [7–9, 16], in a population such
as DS where AD is almost always the cause of dementia,
the lack of specificity is arguably less of an issue, and
NF-L could potentially be used as a biomarker in treat-
ment trials. Recent studies in rodent models of neurode-
generative diseases showed that NF-L levels in CSF and
plasma responded to experimental manipulation and tar-
geted therapy [17], and normalization of serum/plasma
NF-L in response to treatment has already been demon-
strated in patients with multiple sclerosis [8, 18]. These
findings suggest that NF-L may be a useful biomarker of
response to treatment.
The relationship between serum NF-L levels and genetic
markers and other AD biomarkers, including markers of
inflammation and oxidative stress (both of which are
increased in DS and associated with cognitive decline
[19–22]), could also be explored in future research to re-
fine prediction of cognitive decline and to stratify patients
with Down syndrome according to dementia risk for
clinical trials of potential treatments.
Conclusions
Although further work is required to establish long-term
predictive and concurrent validity of NF-L, our data sug-
gest that this biomarker could be instrumental in allow-
ing an experimental medicine approach in individuals
with DS and other high-risk populations to test treat-
ments that might prevent or delay dementia onset.
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